中國醫療集團(08225.HK)旗下專案組研究發現利托那韋對新型冠狀病毒有抑制作用
格隆匯1月29日丨中國醫療集團(08225.HK)公告,中國醫療集團旗下新型冠狀病毒肺炎臨牀特別專案組研究發現利托那韋(Ritonavir)對新型冠狀病毒(2019-nCoV)有抑制作用和療效報告,中國科學院武漢病毒研究所等也發現其在細胞層面上對新型冠狀病毒(2019-nCoV)有較好抑制作用。
目前該集團關聯公司萬全萬特廈門有限公司是一家唯一國內歷史生產過該產品製劑,企業同時擁有原料批文,申請相關專利和已經向國家藥監局申請重新恢復生產。
該集團將負責進一步臨牀研究和申報工作。集團疫情臨牀特別行動組組還在繼續晝夜從上千個可能治療的新老藥品中通過臨牀大數據進行篩選。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.